3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
6
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Anus Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Neoplasms by Site
1
Neoplasm Recurrence, Local
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Disease
1
Dermatitis
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
obinutuzumab
1
ioflupane
1
idelalisib
1
daratumumab
1
alovudine
1
Vindesine
1
Vincristine
1
Rituximab
1
Prednisone
1
Positron Emission Tomography Computed Tomography
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Ga(III)-DOTATOC
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
Bleomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease
×
Mitomycin
×
Clear all
NCT03335059
2020-04-15
RITE-USA
Medical Enterprises Ltd.
Phase 3
Terminated
5 enrolled